Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
Afatinib, the world’s first irreversible ErbB family (containing four different cancer cell epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a second-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It can be used as a fir...
Main Authors: | Yingying Jiang, Xiaoxu Fang, Yan Xiang, Tingwen Fang, Jingwen Liu, Kaihua Lu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/30/6/405 |
Similar Items
-
Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
by: John Wen‐Cheng Chang, et al.
Published: (2023-01-01) -
Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib
by: Chen‐Te Wu, et al.
Published: (2023-09-01) -
Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation
by: Wei Dong, et al.
Published: (2022-11-01) -
CNS efficacy of afatinib as first-line treatment in advanced non-small cell lung cancer patients with EGFR mutations
by: Liping Kang, et al.
Published: (2023-02-01) -
Comparison of efficacy and safety of second‐ and third‐generation TKIs for non‐small‐cell lung cancer with uncommon EGFR mutations
by: Yue Hao, et al.
Published: (2023-08-01)